EP2349199A2 - Pharmaceutical composition for the treatment of periodontal diseases - Google Patents

Pharmaceutical composition for the treatment of periodontal diseases

Info

Publication number
EP2349199A2
EP2349199A2 EP09737192A EP09737192A EP2349199A2 EP 2349199 A2 EP2349199 A2 EP 2349199A2 EP 09737192 A EP09737192 A EP 09737192A EP 09737192 A EP09737192 A EP 09737192A EP 2349199 A2 EP2349199 A2 EP 2349199A2
Authority
EP
European Patent Office
Prior art keywords
mass
pharmaceutical composition
treatment
human
periodontal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09737192A
Other languages
German (de)
English (en)
French (fr)
Inventor
Maciej Siewinski
Jan Wnukiewicz
Beata Wnukiewicz
Katarzyna Malolepsza-Jarmolowska
Jan Nienartowicz
Tadeusz Sebzda
Marek Bryjak
Tadeusz Trziszka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akademia Medyczna Im Piastow Slaskich We Wroclawiu
Original Assignee
Akademia Medyczna Im Piastow Slaskich We Wroclawiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akademia Medyczna Im Piastow Slaskich We Wroclawiu filed Critical Akademia Medyczna Im Piastow Slaskich We Wroclawiu
Publication of EP2349199A2 publication Critical patent/EP2349199A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Definitions

  • composition for the treatment of periodontal diseases is provided.
  • the subject of the present invention is a pharmaceutical composition for the treatment of periodontal disease during both walk-in and hospitalized dentistry, as well as in dental surgery.
  • Periodontitis does not only concern older persons, but also 20 and 30-year olds, and a number of forms are observed in children as well, and constitute the most common cause of tooth loss.
  • Statistical analyses show that inflammatory changes of the gums constitute the most serious cause of tooth loss, and some 60% of the population of the European Union suffers from this problem. This is most often caused by improper oral hygiene and leads to plaque formation, which may be a cause of gingivitis.
  • Periodontitis is aided by some genetic factors, smoking, cavities, over or under-bites, poorly set fillings, hormonal disruptions, the activity of certain drugs or heavy metal poisoning.
  • teeth are supported by the gum, the periodontium or connective tissue between the tooth and the jaw, as well as the jaw bone.
  • the periodontal apparatus is susceptible to inflammation, chiefly due to improper oral hygiene.
  • Periodontal disease including gingivitis
  • gingivitis leads to a disappearance of tissues around the teeth. In most cases, they disappear and leave the neck of the tooth exposed. The disease develops slowly, and symptoms may include bleeding during brushing or flossing, reddened gums, receding gums or plaque. When these problems are not observed sufficiently early, this leads to osteological changes in periodontium, which is evidenced by its increased mobility. The cause of changes in the gums and the bone surrounding the tooth is inflammation. Bacteria accrue in the periodontal space, which cause inflammation, whence the teeth begin to move and fall out. Inflammation is caused by bacteria which settle on the surface of the root of the tooth, which develop underneath the gum, and the inflammation progresses deeper.
  • Cystatin S in saliva inhibits the development of P. gingivalis as well as the activity of cysteine endopeptidases secreted by periodontal bacteria as well as egg protein inhibitors which inhibit the growth of P. gingivalis in vitro in gingival crevice fluid.
  • Bokenvoorde MFJ. Henskens Wim van 't Hot YMC, Amerongen AV N. (1996): Inhibition of the growth and cysteine proteinase activity of porphyromonas gingivalis by human salivary cystatin S and chicken cystatin. Biol. Chern. 377, 847-850).
  • Three cystatins have been isolated from human saliva so far, which are produced in the salivary glands.
  • a curettage is performed. This consists of scraping off the plaque. Bacteria and diseased tissues are thus removed, and the periodontium can heal and regenerate, thus form new tissue. If the disease has destroyed most of the periodontium, and the teeth are poorly held in the bone, they can be bridged, or stiffened. In this procedure, the teeth are connected to one another using various techniques. This may consist of a ligature, or special wires, or a bridging prosthesis, or splints of a composite material. Such a stiff structure of connected teeth stops them from swinging too much. When the wounds in the gums have healed and the periodontium has regenerated, these may be removed.
  • the goal of surgical treatment is to remove disease-altered tissues as well as their regeneration or reformation.
  • a periodontologist has in his arsenal several treatment methods including: root-to-crown, controlled tissue regeneration using implantable barrier membranes, bone grafts of human or animal bone or natural or synthetic bioglass.
  • new tissue is formed which is a copy of the natural one, both in terms of structure and functionality.
  • Of paramount importance is the reconstruction of adhesive function, of the periodontal attachments.
  • a novel preparation, emdogain gives some hope. It contains enamel proteins, the so-called hydrophobic proteins, which stimulate the regeneration of tissues.
  • cysteine peptidase inhibitors are used in the form of preparations purified from various sources, including egg proteins in a composition with vitamins K and D, and the fundamental goal is to rebuild a degraded periodontium and bony periodontal fragments, including the root degraded during periodontitis ( Takada Y., Atsushi Serizawa A., Hidetoshi Ishikawa H., Tomoe Y.,_ Seiichiro Aoe S. (2003) P USA 420102. Bone resorption suppressing agent. Reynolds EC, Bhogal PS., Slakeski N. (2003): Diagnostics and treatments of periodontal disease. P USA 66330 ).
  • Polish patent No. 148352 reveals an agent for the treatment of advanced periodontitis in the form of a cellulose derivative at 3 - 7 % by mass, with a polyhydroxyl alcohol or a polymer thereof at 1 - 5% by mass, with an addition of 0.25 % by mass of Kunitz protease inhibitor and water to 100% by mass.
  • This complex is a hydrophilic gel with thixotropic properties and a high flow threshold, due to which it may be considered a pseudoplastic substance, which makes it resistant to the activity of mechanical factors such as the activity of saliva, beverages and food.
  • Polish patent No. 164585 reveals a therapeutic agent for use in dental surgery, composed of 10-50% gelatin by mass, 2 - 50 % glycerol by mass, or 1.2-propylene glycol, or polyoxyethylene glycol with a molar mass of 200-15000 as well as 1 - 25% by mass of polyvinylpyrolidone with a molar mass of 160000-360000, or polyvinyl alcohol and water to 100% by mass.
  • This substance is dosed into wounds, where it becomes hydrolysed by systemic enzymes, and the hydrolysis products comprising amino acids are resorbed. As the bone becomes replenished, the therapeutic agent diminishes in volume, so it requires no replacement.
  • gelatin a substance of animal origin, ensures resorption due to hydrolysis into amino-acids.
  • Polyvinyl alcohol and polyvinylpyrolidone are also metabolised in the human.
  • the release of therapeutically active substances into the tissues follows a zero-order kinetic process, which ensures a constant concentration of the drug in the tissue.
  • Polish patent No. 311322 releases a dental gel containing 70-90% by mass of a carrier, composed of water physiological saline and a moisturizer, preferentially hydroxyethylcellulose, a plant extract containing tannins and 0.1-5% by mass of sweeteners and aromas.
  • This gel also contains a composition comprising antibiotics such as dethreomycine, colistine, clindamycine in a mass percentage ratio of 1:0.23:5, a steroid anti-inflammatory substance, particularly hydrocortisone at 0.02-1% by mass as well as a plant extract, preferentially of Bergenia, at 1-5 % by mass.
  • the dental gel according to the application in question is useful in the treatment of periodontitis.
  • the present invention relaters to a pharmaceutical composition for the treatment of periodontitis containing at least gel-forming substances.
  • the active substance of the composition is a cysteine protease inhibitor from egg proteins, urine, human and animal amniotic fluid, human and animal placentae, and from plants, which is suspended in 50 g of a polyhydroxyl alcohol, preferentially glycerol, and 50 g of a 0.05 M phosphate buffer solution , pH 6.0 to 7.5, which constitutes a base for the composition in an amount from 20 to 50% by mass, whereas the carrier comprises gelling substances at 7 to 20 % by mass as well as water to 100 % by mass.
  • the gelling substances comprise methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose sodium salt, gelatin, apple- citrus pectin, dextran or a mixture thereof.
  • the composition contains additives in the form of polyhydroxyl alcohols such as glycerol, polyvinylpirolidone K-30 or K-90, polyoxyethylene glycol-200 or glycol propylene-1,2 at 5 to 25 % by mass.
  • polyhydroxyl alcohols such as glycerol, polyvinylpirolidone K-30 or K-90, polyoxyethylene glycol-200 or glycol propylene-1,2 at 5 to 25 % by mass.
  • a preservative is included in the composition, preferentially in the form of Nipagin.
  • compositions in the example sets were used in tests of their ability to treat periodentosis.
  • the observation showed that the activity of cysteine proteases was inhibited in the gingival crevices by specific inhibitors obtained from chicken eggs.
  • the determinations were made on a 30-patient group at the Facial and Jaw clinic of the Medical Academy of Wroclaw. Gingival crevice fluid was collected from two distant crevices from a patient, and then cysteine peptidase activity was quantified, and then inhibited with cystein protease inhibitors. The inhibition exceeded 90%.
  • these inhibitors are suitable for treatment of periodontal inflammations by using appropriate compositions thereof administered directly into periodontal crevices and in mouthwashes for periodontitis patients.
  • compositions using cysteine peptidase inhibitors are easily obtained and inexpensive.
  • the research also indicates the possibility of using other sources of inhibitors in novel drugs, provided that they are not toxic to the human.
  • the research was performed in vitro in fluid collected from the periodontal crevices of patients with diagnosed periodontitis.
  • the base which is also an active substance of the composition, composed of the cysteine peptidase inhibitor, polyhydroxyl alcohol and phosphate buffer solution of an appropriate pH may be maintained at 4°C for up to 12 months.
  • compositions according to the invention are suitable for both prophylaxis as well as in curettage or surgical treatment as a supplemental treatment.
  • the subject of the present invention is shown in example embodiments.
  • BASE cysteine peptidase inhibitor, 1-50 activity units suspended in 50 g glycerol, and 50 g 0.05 M phosphate buffer solution pH 6.0 to 7.5 30.0
  • Nipagin (Aseptins, Parabens) 0.1 Water 48.
  • composition base is prepared by mixing the planned quantities of its components, meaning an appropriate number of units of the cysteine peptidase inhibitor with the polyhydroxyl alcohol and 0.05M phosphate buffer solution with a selected pH. in the range of 6.0 to 7.5.
  • the base is apportioned into plastic or glass containers, and stored, preferentially at 4°C.
  • the measured quantity of base is supplemented with the given quantities of the remaining components and mixed until homogeneity.
  • the gel produced, with a viscosity of 337.53 mPa*s is apportioned into 20 or 50 ml containers.
  • the example composition is meant for rinsing the jaw pocket.
  • Example composition is produced as in Example 1, by first selecting the components, and then apportioning in the same way.
  • the example composition is produced as in Example 1, by first selecting the components, and then apportioning in the same way.
  • the example composition is produced as in Example 1, by first selecting the components, and then apportioning in the same way.
  • the example composition is produced as in Example 1, by first selecting the components, and then apportioning in the same way.
  • the example composition is produced as in Example 1, by first selecting the components, and then apportioning in the same way.
  • Table 1 Inhibition of cysteine peptidases in the gingival crevice fluid by egg protein cystatins using a colorimetric method.
  • Table 2 Inhibition of cysteine peptidases in gingival crevice fluid by egg protein cystatins (5 ⁇ g ). Inhibitor activity (180 imEU/mg protein) using spectrofluorometry.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EP09737192A 2008-08-28 2009-08-28 Pharmaceutical composition for the treatment of periodontal diseases Withdrawn EP2349199A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL385972A PL219098B1 (pl) 2008-08-28 2008-08-28 Kompozycja farmaceutyczna do leczenia chorób przyzębia
PCT/PL2009/050024 WO2010024702A2 (en) 2008-08-28 2009-08-28 Pharmaceutical composition for the treatment of periodontal diseases

Publications (1)

Publication Number Publication Date
EP2349199A2 true EP2349199A2 (en) 2011-08-03

Family

ID=41343718

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09737192A Withdrawn EP2349199A2 (en) 2008-08-28 2009-08-28 Pharmaceutical composition for the treatment of periodontal diseases

Country Status (3)

Country Link
EP (1) EP2349199A2 (pl)
PL (1) PL219098B1 (pl)
WO (1) WO2010024702A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113037A1 (en) * 2011-02-25 2012-08-30 The University Of Melbourne Method for inhibiting proteins
RU2606040C2 (ru) * 2015-04-01 2017-01-10 Ирина Николаевна Усманова Способ лечения хронического воспаления тканей пародонта и слизистой оболочки с элементами гиперкератоза у лиц молодого возраста
RU2637413C1 (ru) * 2016-07-04 2017-12-04 Ирина Николаевна Усманова Способ лечения хронического воспаления слизистой оболочки рта с элементами гиперкератоза у лиц молодого возраста
PL239917B1 (pl) * 2018-11-28 2022-01-24 Univ Medyczny Im Piastow Slaskich We Wroclawiu Kompozycja zawierająca cystatynę oraz jej zastosowanie w implantologii kostnej
WO2020167152A1 (en) * 2019-02-15 2020-08-20 RAPAK, Andrzej Marek Inhibitors of cysteine peptidases isolated from natural raw materials and use of the inhibitors in medicine and veterinary medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4592127B2 (ja) * 1999-03-30 2010-12-01 雪印乳業株式会社 骨吸収抑制剤
PL190404B1 (pl) * 1999-08-02 2005-12-30 Akad Medyczna Środek farmaceutyczny działający przeciwko nowotworom, mikroorganizmom chorobotwórczym i chorobom inwazyjnym
PL195665B1 (pl) * 2000-06-13 2007-10-31 Przed Farmaceutyczne Jelfa Sa Środek farmaceutyczny w postaci żelu do stosowania miejscowego w leczeniu chorób przyzębia
US8283135B2 (en) * 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010024702A2 *

Also Published As

Publication number Publication date
WO2010024702A2 (en) 2010-03-04
WO2010024702A3 (en) 2011-06-03
PL385972A1 (pl) 2010-03-01
PL219098B1 (pl) 2015-03-31

Similar Documents

Publication Publication Date Title
Chen et al. Dental implants: Maintenance, care and treatment of peri‐implant infection
US7115252B2 (en) Therapeutic compositions and methods of use thereof
TWI899058B (zh) 用於治療牙周病之化合物
EP2349199A2 (en) Pharmaceutical composition for the treatment of periodontal diseases
EP1292325B1 (en) Matrix protein compositions for dentin regeneration
US10016492B2 (en) Methods for extracting a tooth
US7304030B2 (en) Matrix protein composition for dentin regeneration
KR102913837B1 (ko) 치주염 치료 및 치간 유두 재생용 조성물
Çiçek et al. Streptococcal gingivitis: A report of case with a description of a unique gingival prothesis
KR20220143012A (ko) 치주염 또는 치은염에 대한 활성 물질로서의 콜라겐 가수분해물
Gamal et al. Guided creeping technique (GCT) as a novel minimally invasive approach in treating limited gingival recession–Case series
RU2821775C1 (ru) Способ поддерживающей терапии при воспалительных заболеваниях пародонта у пациентов пожилого и старческого возраста
Komara et al. Application of Apatite Carbonate Membrane Effect to Bleeding on Probing after Scaling and Root Planing
RU2808463C2 (ru) Композиция для лечения пародонтита и регенерации межзубных сосочков
Henderson Root coverage using Alloderm® acellular dermal graft material
US20070020200A1 (en) Therapeutic compositions and methods of use thereof
Awad et al. Evaluation of The Effect of Socket Shield Technique on The Success of Immediate Dental Implant
Vinogradova et al. The practical usage of the remedy containing an aldehyde group of formaldehyde in vital amputation of the temporary molars
HK40049113A (en) A composition for the treatment of periodontitis and regeneration of interdental papilla
Argento et al. Flapless Technique for Periodontal Bone Grafts in Treatment of Severe Periodontitis. Presentation and Long-Term Retrospective Study. J Microbial Biochem Technol 2: 107-110. doi: 10.4172/1948-5948.1000033
Held The period between 1970 and 1980
EA046983B1 (ru) Кремниевая кислота для применения в лечении периодонтита
EA042241B1 (ru) Лечение гингивита

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TRZISZKA, TADEUSZ

Inventor name: BRYJAK, MAREK

Inventor name: SEBZDA, TADEUSZ

Inventor name: NIENARTOWICZ, JAN

Inventor name: MALOLEPSZA-JARMOLOWSKA, KATARZYNA

Inventor name: WNUKIEWICZ, BEATA

Inventor name: WNUKIEWICZ, JAN

Inventor name: SIEWINSKI, MACIEJ

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TRZISZKA, TADEUSZ

Inventor name: BRYJAK, MAREK

Inventor name: SEBZDA, TADEUSZ

Inventor name: NIENARTOWICZ, JAN

Inventor name: MALOLEPSZA-JARMOLOWSKA, KATARZYNA

Inventor name: WNUKIEWICZ, BEATA

Inventor name: WNUKIEWICZ, JAN

Inventor name: SIEWINSKI, MACIEJ

17P Request for examination filed

Effective date: 20111205

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120522

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160301